R
Rachael Hunter
Researcher at University College London
Publications - 169
Citations - 3722
Rachael Hunter is an academic researcher from University College London. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 26, co-authored 139 publications receiving 2462 citations. Previous affiliations of Rachael Hunter include University of Manchester.
Papers
More filters
Journal ArticleDOI
Placental Growth Factor (PlGF) in Women with Suspected Pre-Eclampsia Prior to 35 Weeks' Gestation: A Budget Impact Analysis.
TL;DR: This analysis suggests PlGF used as part of a clinical management algorithm in women presenting with suspected pre-eclampsia prior to 35 weeks’ gestation could provide cost savings by reducing unnecessary resource use.
Journal ArticleDOI
Femtosecond laser-assisted cataract surgery compared with phacoemulsification cataract surgery: randomized noninferiority trial with 1-year outcomes.
Alexander C Day,Jennifer Burr,Kate Bennett,Caroline J Doré,Catey Bunce,Rachael Hunter,Mayank A. Nanavaty,Kamaljit S. Balaggan,Mark R Wilkins +8 more
TL;DR: PCS is not inferior to FLACS in terms of vision, patient reported health and safety outcomes after one year follow-up, and FLACs is not cost effective.
Journal ArticleDOI
Healthcare resource utilisation and costs of agitation in people with dementia living in care homes in England: The Managing Agitation and Raising QUality of LifE in Dementia (MARQUE) study
Monica Panca,Gill Livingston,Julie Barber,Claudia Cooper,Francesca La Frenais,Louise Marston,Sian Cousins,Rachael Hunter +7 more
TL;DR: Agitation in people with dementia living in care homes contributes significantly to the overall costs increasing as the level of agitation increases, suggesting that effective strategies to reduce agitation are likely to be cost-effective in this setting.
Journal ArticleDOI
Using 'payment by results' to fund the treatment of dependent drug users-proceed with care!
TL;DR: The UK government is changing its system of payment for drug treatment services in order to reward the achievement of better patient outcomes, and this model may be taken up internationally.
Journal ArticleDOI
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study.
Nirosen Vijiaratnam,Nirosen Vijiaratnam,Christine Girges,Christine Girges,Grace Auld,Marisa Chau,Kate Maclagan,Alexa King,Simon S. Skene,Kashfia Chowdhury,Steve Hibbert,Huw R. Morris,Huw R. Morris,Patricia Limousin,Patricia Limousin,Dilan Athauda,Dilan Athauda,Camille Carroll,Michele T.M. Hu,Monty Silverdale,Gordon W Duncan,Gordon W Duncan,Ray Chaudhuri,Christine Lo,Silvia Del Din,Alison J. Yarnall,Lynn Rochester,Rachel J. Gibson,John Dickson,Rachael Hunter,Vincenzo Libri,Thomas Foltynie,Thomas Foltynie +32 more
TL;DR: In this paper, a phase 3, multicentre, double-blind, randomised, placebo-controlled trial of exenatide at a dose of 2 mg weekly in 200 participants with mild to moderate Parkinson's disease was presented.